Core Insights - Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing Superkines for cancer and autoimmune diseases, participating in several upcoming conferences to showcase its innovative therapies and engage with the investment community [1][5]. Upcoming Conference Participation - Medicenna will participate in the Planet MicroCap Showcase in Toronto in 2025, BIO-Europe 2025 in Vienna, and the Oppenheimer Miami Oncology Summit [2][3][4]. - The BIO-Europe event is one of the largest life sciences partnering events, providing Medicenna a platform to engage with potential partners and investors [7]. - The Oppenheimer Miami Oncology Summit will focus on oncology advancements, allowing Medicenna to discuss its immunotherapy innovations [7]. Company Overview - Medicenna is developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, including the long-acting IL-2 Superkine, MDNA11, which preferentially stimulates cancer-killing effector T cells and NK cells [5]. - The IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials with over 130 patients, including a Phase 2b trial for recurrent GBM, and has received FastTrack and Orphan Drug status from the FDA and EMA [5]. - Medicenna's early-stage BiSKITs™ and T-MASK™ programs aim to enhance the effectiveness of Superkines in treating immunologically "cold" tumors [5].

Core Insights - Medicenna Therapeutics Corp. is a clinical-stage cancer immunotherapy company focused on developing Superkines [1][4] - Dr. Fahar Merchant, President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1][2] - The company is developing novel versions of IL-2, IL-4, and IL-13 Superkines, with a focus on enhancing cancer treatment [4] Presentation Details - The presentation is scheduled for September 9, 2025, from 2:30 PM to 3:00 PM (Eastern Standard Time) at the Lotte New York Palace Hotel [2] - A webcast of the presentation will be available for 90 days on Medicenna's investor relations website [2] Company Overview - Medicenna's long-acting IL-2 Superkine, MDNA11, has superior affinity toward CD122 and preferentially stimulates cancer-killing effector T cells and NK cells [4] - The IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials with over 130 patients, including a Phase 2b trial for recurrent GBM [4] - Bizaxofusp has received FastTrack and Orphan Drug status from the FDA and EMA [4] - Medicenna is also developing early-stage BiSKITs™ and T-MASK™ programs aimed at treating immunologically "cold" tumors [4]

Core Insights - Medicenna Therapeutics is advancing its MDNA11 program, demonstrating significant anti-tumor activity in difficult-to-treat solid tumors, with response rates between 30-50% in various cohorts [1][5] - The company plans to solidify its Phase 2b development strategy for MDNA11 by the end of 2025, including strategies for accelerated approval [12] - Medicenna's MDNA113, a first-in-class PD-1 x IL-2 bispecific Superkine, is progressing to non-human primate studies in the second half of 2025 [1][12] Clinical Development - MDNA11 is currently in a Phase 1/2 clinical trial, with a recommended dose of 90 µg/kg administered intravenously every two weeks [4] - A pancreatic cancer patient treated with MDNA11 has remained in remission for at least 18 months without further treatment, showcasing the drug's potential [2][5] - The company aims to complete enrollment in the Phase 1/2 ABILITY-1 trial and report top-line data from both monotherapy and combination arms by the end of 2025 [2][12] Financial Performance - For the fiscal year ended March 31, 2025, Medicenna reported total operating costs of $20.4 million, an increase from $18.7 million in the previous year, primarily due to higher research and development expenses [9][11] - The net loss for the year was $11.8 million, a decrease from $25.5 million in the prior year, attributed to a reduction in the fair value of the derivative warrant liability [10] - Medicenna ended the fiscal year with cash and cash equivalents of $24.8 million, expected to fund operations through mid-2026 [8] Research and Development - Research and development expenses increased to $14.4 million for the year ended March 31, 2025, driven by expanded clinical costs and the inclusion of combination studies with KEYTRUDA [11] - The company is pursuing partnership opportunities for its phase-3 ready IL-4 Superkine, Bizaxofusp, which has received FastTrack and Orphan Drug status from the FDA [7] - MDNA113 is designed to address safety issues associated with current anti-PD-1 candidates while maintaining efficacy in challenging tumor types [2][12]